JP2017515902A - 脂血及び体重を制御する薬物組成物とその応用法 - Google Patents
脂血及び体重を制御する薬物組成物とその応用法 Download PDFInfo
- Publication number
- JP2017515902A JP2017515902A JP2017512078A JP2017512078A JP2017515902A JP 2017515902 A JP2017515902 A JP 2017515902A JP 2017512078 A JP2017512078 A JP 2017512078A JP 2017512078 A JP2017512078 A JP 2017512078A JP 2017515902 A JP2017515902 A JP 2017515902A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- preparation
- decoction
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000037396 body weight Effects 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims description 42
- 229940079593 drug Drugs 0.000 title claims description 39
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 24
- 108010010234 HDL Lipoproteins Proteins 0.000 claims abstract description 13
- 102000015779 HDL Lipoproteins Human genes 0.000 claims abstract description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 claims abstract description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 12
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 11
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 8
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 8
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 8
- 208000024891 symptom Diseases 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 29
- 241000411851 herbal medicine Species 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 244000144730 Amygdalus persica Species 0.000 claims description 12
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 12
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 229940010454 licorice Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229940116269 uric acid Drugs 0.000 claims description 8
- 241000202807 Glycyrrhiza Species 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 238000001467 acupuncture Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000011812 mixed powder Substances 0.000 claims description 4
- 241000723438 Cercidiphyllum japonicum Species 0.000 claims description 3
- 235000011511 Diospyros Nutrition 0.000 claims description 3
- 244000236655 Diospyros kaki Species 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 45
- 239000000243 solution Substances 0.000 description 25
- 230000002354 daily effect Effects 0.000 description 18
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 10
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 10
- 229960005370 atorvastatin Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 241000736199 Paeonia Species 0.000 description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000017803 cinnamon Nutrition 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 239000013583 drug formulation Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000489438 Cinchona pubescens Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002402 anti-lipaemic effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- -1 tinctures Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000009506 keishibukuryogan Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
Description
A群:丹皮と桂枝
B群:丹皮、桂枝、桃仁と甘草
C群:丹参、姜黄と黄連
(1) 生薬を粉砕して混合して、生薬混合粉を生成する過程と、
(2) 過程(1)で得られた生薬混合粉に水を加えて浸した(優先的選択は0.5〜2時間浸す)後、非密閉容器中で煎じ(優先的選択は0.5〜2時間煎じる)、煎出液を得る過程と、
(3) 過程(2)で得られた煎出液を濾過して薬液を得る過程と、
(4) 過程(3)で得られた薬液を任意選択(優先的選択は冷凍乾燥)にて乾燥する過程とを含む。
(1) 生薬を粉砕し混合して生薬混合粉を生成する過程と、
(2) 過程(1)で得られた生薬混合粉に水を加えて浸した(優先的選択は0.5〜2時間浸す)後、非密閉容器中で煎じ(優先的選択は0.5〜2時間煎じる)て煎出液を得る過程と、
(3) 過程(2)で得られた煎出液を濾過して薬液を得る過程と、
(4) 過程(3)で得られた薬液を任意選択(優先的選択は冷凍乾燥)にて乾燥する過程とを含む。
Claims (10)
- 茯苓、芍薬及び下記A群、B群及びC群:
A群:丹皮と桂枝
B群:丹皮、桂枝、桃仁と甘草
C群:丹参、姜黄と黄連
の1つの生薬から調製されたことを特徴とする脂血及び/又は体重の制御に用いる中医薬組成物。 - 各生薬の重量部は、茯苓:約3重量部、芍薬:約3重量部、丹皮:約3重量部、桂枝:約3重量部、桃仁:約3重量部、甘草:約2重量部、丹参:約3重量部、姜黄:約3重量部、黄連:約1.2重量部である請求項1に記載の中医薬組成物。
- 前記調製過程は、水及び/又はアルコールからなる媒質を生薬に配合して煎じる過程を含み、優先的選択は、水を配合して、非密閉容器中で生薬を煎じる過程である請求項1に記載の中医薬組成物。
- 前記調製過程として、
(1) 生薬を粉砕して混合して生薬混合粉を生成する過程と、
(2) 過程(1)で生成した生薬混合粉に水を加えて浸した後(優先的選択は、0.5〜2時間水浸す)、非密閉容器の中で煎じ(優先的選択は0.5〜2時間煎じる)て、煎出液を得る過程と、
(3) 過程(2)で得られた煎出液を濾過して薬液を生成する過程と、
(4) 過程(3)で生成した薬液を任意選択(優先的選択は、冷凍乾燥)にて乾燥させる過程とを含む請求項3に記載の中医薬組成物。 - 体内総コレステロール量の低減、体内トリグリセリド量の低減、体内低密度リポタンパク質の量の低減、体内高密度リポタンパク質の量の向上、体内尿酸量の低減かつ/又は脂肪肝の症状の改善に用いられる請求項1に記載の中医薬組成物。
- 請求項1〜5の何れかに記載の中医薬組成物の調製方法において、
(1) 生薬を粉砕して混合して生薬混合粉を生成する過程と、
(2) 過程(1)で生成した生薬混合粉に水を加えて浸した後(優先的選択は、0.5〜2時間水浸す)、非密閉容器の中で煎じ(優先的選択は0.5〜2時間煎じる)て、煎出液を得る過程と、
(3) 過程(2)で得られた煎出液を濾過して薬液を生成する過程と、
(4) 過程(3)で生成した薬液を任意選択(優先的選択は、冷凍乾燥)にて乾燥させる過程とを含むことを特徴とする調製方法。 - 脂血及び/又は体重の制御に用いる中医薬製剤において、
請求項1〜5の何れかに記載の中医薬組成物及び薬学上許容される補助材料を含むことを特徴とする中医薬製剤。 - 粉剤(優先的選択は、冷凍乾燥粉剤)又は液体製剤に加工され又は製剤化された請求項7に記載の中医薬製剤。
- 請求項1〜5の何れかに記載の中医薬組成物の脂血及び/又は体重の制御に用いられることを特徴とする薬物製剤の応用法。
- 請求項1〜5の何れかに記載の中医薬組成物の体内総コレステロール量の低減、体内トリグリセリド量の低減、体内低密度リポタンパク質の量の低減、体内高密度リポタンパク質の量の向上、体内尿酸量の低減、及び/又は脂肪肝の症状の改善に使用されることを特徴とする薬物製剤の調製応用法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410197015 | 2014-05-12 | ||
CN201410197015.1 | 2014-05-12 | ||
PCT/CN2014/000968 WO2015172273A1 (zh) | 2014-05-12 | 2014-11-04 | 控制人体血脂和体重的药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017515902A true JP2017515902A (ja) | 2017-06-15 |
JP6626093B2 JP6626093B2 (ja) | 2019-12-25 |
Family
ID=54479104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017512078A Active JP6626093B2 (ja) | 2014-05-12 | 2014-11-04 | 中医薬組成物及びその調整方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10548940B2 (ja) |
JP (1) | JP6626093B2 (ja) |
CN (1) | CN106535912B (ja) |
DE (1) | DE112014006651T5 (ja) |
WO (1) | WO2015172273A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102130044B1 (ko) * | 2018-03-23 | 2020-07-03 | 한국한의학연구원 | 천연 혼합 추출물을 포함하는 비만 예방 또는 치료용 조성물 |
CN109645482A (zh) * | 2019-01-09 | 2019-04-19 | 安徽亳药千草国药股份有限公司 | 一种利尿茯苓保健品的制备方法 |
CN110354084A (zh) * | 2019-08-23 | 2019-10-22 | 辽宁中医药大学 | 一种胆黄连配方颗粒的制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002053476A (ja) * | 2000-08-07 | 2002-02-19 | Asahi Breweries Ltd | 高脂血症予防兼改善剤およびそれを含有する飲食品 |
JP2002114695A (ja) * | 2000-09-21 | 2002-04-16 | Ready Made 37 (1999) Ltd | 薬物として使用するための甘草抽出物 |
JP2005206589A (ja) * | 2003-12-26 | 2005-08-04 | Taisho Pharmaceut Co Ltd | リパーゼ阻害剤 |
JP2006298896A (ja) * | 2005-03-22 | 2006-11-02 | Iskra Ind Co Ltd | 高脂血症改善剤、動脈硬化改善剤及び肝機能改善剤 |
JP2008133272A (ja) * | 2006-10-31 | 2008-06-12 | Ito En Ltd | Cpt活性亢進剤及び飲食物 |
CN101214352A (zh) * | 2007-01-05 | 2008-07-09 | 闫淑丽 | 一种治疗高脂血症的中药 |
JP2009114179A (ja) * | 2008-10-09 | 2009-05-28 | Tsujido Kagaku Kk | 治療剤 |
JP2010227033A (ja) * | 2009-03-27 | 2010-10-14 | Japan Health Science Foundation | 植物形質転換体の作出方法、及び、植物形質転換体 |
CN102240372A (zh) * | 2011-06-21 | 2011-11-16 | 武汉市中医医院 | 一种治疗痛风性关节炎和高尿酸血症的药物及制备方法 |
CN102846760A (zh) * | 2011-06-30 | 2013-01-02 | 苏州知微堂生物科技有限公司 | 一种桂枝茯苓汤整合型新剂型制备技术及其生产方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1154714C (zh) | 1999-11-12 | 2004-06-23 | 海南黎王醉椰酒业有限公司 | 一种天然椰子酒的制造方法 |
CN100586425C (zh) | 2003-12-10 | 2010-02-03 | 江西欧氏药业有限责任公司 | 桂枝茯苓软胶囊及其制备工艺 |
CN1278719C (zh) | 2004-12-31 | 2006-10-11 | 邓小安 | 一种治疗前列腺肥大的中药贴剂及其生产方法 |
CN1748738A (zh) | 2005-09-17 | 2006-03-22 | 浙江天一堂集团有限公司 | 中药桂枝茯苓滴丸及其制备方法 |
CN1985913A (zh) | 2005-12-19 | 2007-06-27 | 珠海天翼医药技术开发有限公司 | 桂枝茯苓微丸的制备方法 |
CN101564442A (zh) | 2008-04-25 | 2009-10-28 | 北京和润创新医药科技发展有限公司 | 一种桂枝茯苓制剂及其制备方法 |
CN101310739B (zh) | 2008-07-11 | 2011-05-25 | 西安天健医药科学研究所 | 一种桂枝茯苓组合物及其制备方法 |
CN101491606B (zh) | 2008-12-31 | 2011-11-30 | 四川禾邦阳光制药股份有限公司 | 一种桂枝茯苓微丸及其制备方法 |
CN101757562B (zh) * | 2009-11-05 | 2011-03-23 | 泰一和浦(北京)中医药研究院有限公司 | 一种治疗肝脏中期恶性肿瘤病证的中药组合物及其制备方法 |
CN102188560A (zh) | 2010-03-08 | 2011-09-21 | 张锡林 | 中药治疗高血脂 |
CN102085257B (zh) | 2011-01-12 | 2012-04-04 | 山东省中医药研究院 | 一种桂枝茯苓微丸的制备方法 |
CN102908599A (zh) | 2012-06-19 | 2013-02-06 | 谢文龙 | 一种降糖降脂降压的药物 |
CN102772517B (zh) | 2012-07-26 | 2014-06-04 | 成都九芝堂金鼎药业有限公司 | 一种桂枝茯苓丸的制备方法 |
-
2014
- 2014-11-04 DE DE112014006651.6T patent/DE112014006651T5/de active Pending
- 2014-11-04 JP JP2017512078A patent/JP6626093B2/ja active Active
- 2014-11-04 WO PCT/CN2014/000968 patent/WO2015172273A1/zh active Application Filing
- 2014-11-04 US US15/310,897 patent/US10548940B2/en active Active
- 2014-11-04 CN CN201480078792.2A patent/CN106535912B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002053476A (ja) * | 2000-08-07 | 2002-02-19 | Asahi Breweries Ltd | 高脂血症予防兼改善剤およびそれを含有する飲食品 |
JP2002114695A (ja) * | 2000-09-21 | 2002-04-16 | Ready Made 37 (1999) Ltd | 薬物として使用するための甘草抽出物 |
JP2005206589A (ja) * | 2003-12-26 | 2005-08-04 | Taisho Pharmaceut Co Ltd | リパーゼ阻害剤 |
JP2006298896A (ja) * | 2005-03-22 | 2006-11-02 | Iskra Ind Co Ltd | 高脂血症改善剤、動脈硬化改善剤及び肝機能改善剤 |
JP2008133272A (ja) * | 2006-10-31 | 2008-06-12 | Ito En Ltd | Cpt活性亢進剤及び飲食物 |
CN101214352A (zh) * | 2007-01-05 | 2008-07-09 | 闫淑丽 | 一种治疗高脂血症的中药 |
JP2009114179A (ja) * | 2008-10-09 | 2009-05-28 | Tsujido Kagaku Kk | 治療剤 |
JP2010227033A (ja) * | 2009-03-27 | 2010-10-14 | Japan Health Science Foundation | 植物形質転換体の作出方法、及び、植物形質転換体 |
CN102240372A (zh) * | 2011-06-21 | 2011-11-16 | 武汉市中医医院 | 一种治疗痛风性关节炎和高尿酸血症的药物及制备方法 |
CN102846760A (zh) * | 2011-06-30 | 2013-01-02 | 苏州知微堂生物科技有限公司 | 一种桂枝茯苓汤整合型新剂型制备技术及其生产方法 |
Non-Patent Citations (6)
Title |
---|
DIABETES RES CLIN PRACTICE., 2008, VOL.80, P.40-47, JPN6018019605, ISSN: 0003974209 * |
J CHANGCHUN COLLEGE TRADITIONAL CHINESE MEDICINE., 1997, VOL.13, P.14, JPN6018019609, ISSN: 0003974211 * |
J PHARMACY PHARMACOLOGY, 2003, VOL.55, P.219-227, JPN6018019607, ISSN: 0003974210 * |
プロジェクト研究報告書 漢方方剤・生薬の品質と生体作用に関する研究, 2000, P.5-10, JPN6018019615, ISSN: 0003806356 * |
中薬大辞典 第三巻, 上海科学技術出版社 小学館編, 株式会社小学館発行, 1998, P.1729-1733, JPN6018019613, ISSN: 0003974213 * |
肝臓, 2007, VOL.48 SUPPL, P.A556(O-78), JPN6018019611, ISSN: 0003974212 * |
Also Published As
Publication number | Publication date |
---|---|
US20170080043A1 (en) | 2017-03-23 |
US10548940B2 (en) | 2020-02-04 |
DE112014006651T5 (de) | 2017-02-09 |
CN106535912A (zh) | 2017-03-22 |
CN106535912B (zh) | 2018-01-23 |
JP6626093B2 (ja) | 2019-12-25 |
WO2015172273A1 (zh) | 2015-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008106821A1 (fr) | Composition médicinale chinoise et extrait de larves associé et leur préparation | |
JP6626093B2 (ja) | 中医薬組成物及びその調整方法 | |
WO2014201637A1 (zh) | 一种治疗神经根型颈椎病的复方制剂及其制备方法 | |
CN101757374B (zh) | 一种制备治疗烧烫伤的药剂及其制备方法 | |
CN102552719A (zh) | 一种羚羊感冒胶囊制备过程中挥发油的添加方法 | |
CN114377095A (zh) | 一种砂仁-檀香挥发油提取方法、治疗胃炎的胶囊及其制备方法 | |
CN108096318A (zh) | 治疗心脑血管疾病的药物组合物及其制备方法和用途 | |
CN107375829A (zh) | 治疗中风后抑郁症的中药组合物及其制剂的制备方法 | |
CN107997170B (zh) | 一种具有降血脂功能的组合物及其制备方法 | |
CN100998696A (zh) | 一种治疗咽喉疾病的中药组合物及其制备方法 | |
CN100542517C (zh) | 牛黄解毒滴丸及其制备方法 | |
CN1278731C (zh) | 复方柴胡药物制剂 | |
JP2004500313A (ja) | 天然薬用植物およびその前処理物からの活性成分を有する粉末入浴用製剤 | |
CN103800449B (zh) | 一种治疗阴虚热盛证2型糖尿病的中药组合物 | |
CN102406790A (zh) | 一种治疗乳腺增生疾病的中药胶囊及其制备方法 | |
CN107050187A (zh) | 一种治疗阳痿、早泄的中药组合物及其制备方法 | |
CN107261057B (zh) | 用于治疗抑郁症的中药组合物及其制备方法 | |
CN101670007A (zh) | 一种预防和治疗肾脏疾病的药物及其制备方法 | |
CN101317936A (zh) | 一种舒肝解郁胶囊的制作方法 | |
CN106511631A (zh) | 一种用于治疗前列腺炎的前列平制剂及其制备方法 | |
CN106853193A (zh) | 一种治疗类风湿性关节炎的中药及其制备方法 | |
CN105663529A (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
CN104069423B (zh) | 一种具有抗癌作用的中药组合物及其制备方法和用途 | |
CN113476575A (zh) | 一种用于治疗阿尔茨海默病的中药组合物及其制备方法 | |
CN115671219A (zh) | 一种治疗痛风的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171024 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180605 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190813 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6626093 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |